ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2007
Antimicrobial therapy for Stenotrophomonas maltophilia infections.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 1 synthesis or guideline pooled it, 242 citations in OpenAlex.
- Global prevalence and antibiotic resistance in clinical isolates ofFrontiers in medicine · 2023Pooled it
- Shifting Epidemiology ofJournal of clinical medicine · 2026Article
- Article
- Navigating the Challenges ofClinical case reports · 2026Article
- The Other Face ofAntibiotics (Basel, Switzerland) · 2026Article
- Risk factors and clinical characteristics for Stenotrophomonas maltophilia infection in an acute care hospital in Japan: a single-center retrospective study.Journal of pharmaceutical health care and sciences · 2025Article
- Characterization and antimicrobial activity of a novel lytic phage vB_SmaS_QH16 againstFrontiers in cellular and infection microbiology · 2025Article
- Characterization of the novel cross-genus phage vB_SmaS_QH3 and evaluation of its antibacterial efficacy againstFrontiers in microbiology · 2025Article
- Impact of Empirical Antimicrobial Treatment on Patients with Ventilator-Associated Pneumonia Due toAntibiotics (Basel, Switzerland) · 2024Article
- Deciphering the Coevolutionary Dynamics of L2 β-Lactamases via Deep Learning.Journal of chemical information and modeling · 2024Article
- Ventilation Management in a Patient with Ventilation-Perfusion Mismatch in the Early Phase of Lung Injury and during the Recovery.Journal of clinical medicine · 2024Article
- Rapid and visual identification of β-lactamase subtypes for precision antibiotic therapy.Nature communications · 2024Article
- Antibiotic Resistance and Virulence Factors in Clinical Isolates ofInternational journal of microbiology · 2024Article
- Antibiotic utilization trends in Veterans Affairs patients withAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- First Report ofLife (Basel, Switzerland) · 2023Article
- Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group.Annals of hematology · 2023Article
- Novel Antibiotic Resistance Genes Identified by Functional Gene Library Screening inInternational journal of molecular sciences · 2023Article
- Bacterial resistance to antibacterial agents: Mechanisms, control strategies, and implications for global health.The Science of the total environment · 2023Review
- Necrotizing Pancreatitis Infected withCase reports in gastrointestinal medicine · 2023Article
- Comparative genomics analysis ofFrontiers in cellular and infection microbiology · 2023Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stenotrophomonas maltophilia has emerged as an important nosocomial pathogen capable of causing respiratory, bloodstream, and urinary infections. The treatment of nosocomial infections by S. maltophilia is difficult, as this pathogen shows high levels of intrinsic or acquired resistance to different antimicrobial agents, drastically reducing the antibiotic options available for treatment. Intrinsic resistance may be due to reduced outer membrane permeability or to the multidrug efflux pumps. However, specific mechanisms of resistance such as aminoglycoside-modifying enzymes or the heterogeneous production of metallo-beta-lactamase have contributed to the multidrug-resistant phenotype displayed by this pathogen. Moreover, the lack of standardized susceptibility tests and their interpretative criteria hinder the choice of an adequate antibiotic treatment. Recommendations for the treatment of infections by S. maltophilia are based on in vitro studies, certain nonrandomized clinical trials, and anecdotal experience. Trimethoprim-sulfamethoxazole remains the drug of choice, although in vitro studies indicate that ticarcillin-clavulanic acid, minocycline, some of the new fluoroquinolones, and tigecycline may be useful agents. This review describes the main resistance mechanisms, the in vitro susceptibility profile, and treatment options for S. maltophilia infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.